Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 657 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New on NCI’s Websites for December 2023 December 28, 2023 How to Clean Your Home When Caring for Someone With Cancer October 7, 2020 ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act June 11, 2025 ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... October 20, 2020 Load more HOT NEWS Rate of Suicides Related to Cancer Is Declining Coronavirus reports – Part 9: “I am very relieved but I... FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ
